Co-Authors
This is a "connection" page, showing publications co-authored by Shibo Jiang and Xia Cai.
Connection Strength
0.745
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.229
-
Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. Virol Sin. 2020 12; 35(6):857-860.
Score: 0.227
-
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021 07 29; 6(1):288.
Score: 0.060
-
Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021 02 08; 12(1):866.
Score: 0.058
-
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021 02 02; 34(5):108699.
Score: 0.058
-
Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection. Cell Res. 2021 01; 31(1):98-100.
Score: 0.057
-
Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27141-27147.
Score: 0.057